Key result
An abnormal ABCDE stress echocardiography protocol across all five steps was associated with a mortality rate of 2.7%/year compared with 0.4%/year for a normal test.
Why the study?
Does the ABCDE stress echocardiography protocol improve risk stratification for mortality in patients with suspected or known CAD?
Does the ABCDE stress echocardiography protocol improve risk stratification for mortality in patients with suspected or known CAD?
Answers are grounded in this paper and cite their sources.
The ABCDE stress echocardiography protocol provides improved risk stratification for mortality in patients with suspected or known CAD compared to traditional ischemia testing alone.
This editorial refers to ‘Prognostic value of stress echocardiography assessed by the ABCDE protocol’, by Q. Ciampi et al., doi: 10.1093/eurheartj/ehab493. Modification of the ABCDE stress echo protocol incorporating the use of ultrasound contrast agents and carotid ultrasonography addressing the constellation of imaging substrates to further improve the diagnosis and risk stratification of coronary artery disease. CFR = coronary flow reserve; LAD = left anterior descending artery; MCE = myocardial contrast echocardiography; RWTA = regional wall thickening abnormality; LVD = left ventricular dysfunction; LVCR = left ventricular contractile reserve; HRR = heart rate reserve. Modification of the ABCDE stress echo protocol incorporating the use of ultrasound contrast agents and carotid ultrasonography addressing the constellation of imaging substrates to further improve the diagnosis and risk stratification of coronary artery disease. CFR = coronary flow reserve; LAD = left anterior descending artery; MCE = myocardial contrast echocardiography; RWTA = regional wall thickening abnormality; LVD = left ventricular dysfunction; LVCR = left ventricular contractile reserve; HRR = heart rate reserve. Stress echocardiography (SE) has evolved into one of the leading investigation tools for the assessment of coronary artery disease (CAD).1 Its ubiquitous nature, portability, relatively low cost, and avoidance of ionizing radiation exposure makes it an attractive choice of test for a wide variety of patients. The premise on which SE detects CAD is the identification of regional wall thickening abnormalities (RWTAs) which when precipitated by physiological exercise or pharmacological stress suggest myocardial ischaemia. Because SE can be performed during exercise, prognostic parameters such as exercise duration, blood pressure response, ST–T changes, and left ventricular (LV) dilatation can be simultaneously assessed, and these further enhance its diagnostic and prognostic value. Its clinical value for both the diagnosis and risk stratification of CAD is recognized by international societies, conferring on it a Class 1A indication for the evaluation of CAD.1 Over the last decade, improved lifestyle measures have led to a significant decline in obstructive CAD in developed countries from 30–40% to ∼12%.2,3 This has ameliorated the prognostic value of functional testing strategies which rely solely on delineation of myocardial ischaemia as a marker of CAD. The study published in this issue of the European Heart Journal by Ciampi et al. from Picano’s group recognizes this fact and explored the concept that functional testing with SE may detect other biomarkers, beyond myocardial ischaemia, which might improve risk stratification in those with suspected or known CAD.4 The authors assessed pathophysiological processes that might occur as a consequence of, or independently from, the development of stress-induced ischaemia including reduced coronary flow reserve (CFR), blunted LV contractile response (CR), autonomic dysfunction, and transient pulmonary congestion. Their stepwise SE protocol incorporated (i) the detection of RWTAs for ischaemia (step A); (ii) the identification of lung B lines as a surrogate marker of LV systolic or diastolic dysfunction by performing lung ultrasound (step B); (iii) the identification of LVCR using afterload-adjusted end-systolic volume assessment (step C); (iv) the assessment of Doppler-based CFR which may even be reduced in non-obstructive CAD and in microvascular disease (step D); and finally (v) the assessment of heart rate reserve (HRR), a measure of autonomic dysfunction which may occur in a variety of cardiac diseases other than CAD. In a multicentre study, the authors prospectively recruited 3574 patients with suspected or known CAD referred for SE. All steps were normal in 31% of patients and all steps were abnormal in 5% of patients. Of those with normal SE who underwent coronary angiography, 30% demonstrated obstructive CAD, whereas in those with all five abnormal steps on SE, 95% had significant CAD. The mortality rate was 0.4%/year for a normal SE compared with 2.7%/year when all SE steps were abnormal. These data underscore the feasibility and improved risk stratification information provided by the ABCDE SE protocol. The authors acknowledge that the ABCDE protocol could be further refined by grading the severity of abnormalities at each step of the protocol rather than using a binary approach. Although the type of stress modality was not found to be a predictor of outcome, and abnormalities of LVCR and HRR were corrected for the type of stress used, it is notable that the majority of those with high SE scores of 4 or 5 underwent exercise testing. Indeed, from the clinical standpoint, it seems more intuitive and clinically relevant to perform physiological exercise rather than pharmacological stress when using the ABCDE protocol particularly when assessing LVCR and autonomic function. Therefore, it would be of greater interest to evaluate the efficacy of the ABCDE protocol with exercise and compare the relative predictive value of each stress modality when using the stepwise SE protocol. Indeed, in this study, the majority of patients underwent dipyridamole stress, and LVCR was not a predictor of mortality. Exercise duration may also be another important prognostic marker. Interestingly, the finding of myocardial ischaemia was not associated with mortality, most likely because appropriate disease-modifying medications and coronary interventions were implemented in the interim. Many patients may also have been tested on anti-ischaemic therapy, masking ischaemia particularly in those undergoing dipyridamole stress. In addition, ultrasound contrast agents (UCAs) for LV opacification5,6 were underutilized in this study and this may have led to under-reporting of RWTAs and ischaemia. Furthermore, because SE relies on the detection of inducible RWTAs for diagnosing CAD, the myocardial oxygen demand should significantly exceed myocardial blood supply in order to identify ischaemic myocardium. This reflects the need for significant obstructive coronary artery lesions supplying a fair extent of the myocardium which may not be the case in milder lesions subtending limited single vessel territories.7 This may also explain why, when SE was normal in those who underwent coronary angiography, 30% demonstrated mainly single vessel CAD. Thus, to enhance the detection of myocardial ischaemia, UCAs could also have been used to assess myocardial perfusion. With the development of contrast-specific imaging modalities for myocardial perfusion assessment, several studies have shown that myocardial contrast echocardiography (MCE) not only improves the sensitivity of SE for the detection of CAD, but also improves risk stratification beyond the demonstration of inducible RWTAs.6 As perfusion abnormalities occur earlier than RWTAs during ischaemia, and because MCE also detects microcirculatory abnormalities in those with and without CAD, MCE improves the sensitivity for the detection of flow-limiting CAD and enhances risk stratification in these patients.6,8 Consequently, MCE is a recognized technique for the assessment of CAD in European guidelines and should be incorporated in a SE protocol.1,6 Nevertheless, the limitations of ischaemia testing for prognosis have recently been acknowledged, particularly in comparison with coronary atherosclerosis imaging by coronary computed tomographic angiography (CCTA).2,9 A post-hoc analysis of the PROMISE trial in patients with suspected angina found that although the prevalence of CAD by CCTA was 67%, obstructive coronary lesions, defined as ≥70% stenosis, were present in only 12% of patients.2 The presence of obstructive CAD on CCTA, or myocardial ischaemia on functional testing, was associated with similar event rates of 8–9% over 2 years compared with a 3% event rate in those with non-obstructive CAD on CCTA (1–69% stenosis). A normal CCTA, showing complete absence of CAD, conferred an event rate of 0.9% compared with a normal functional test which was associated with a significantly higher event rate of 2% over 2 years. The latter finding may reflect the presence of non-obstructive CAD which remains undetected by functional testing, but may nevertheless cause future events through plaque rupture. Consequently, it is important to identify non-obstructive CAD in order to enhance risk stratification and implement preventative treatment such as statins and antiplatelet therapy. As atherosclerosis is a global process, the use of carotid ultrasound for the detection of atherosclerotic plaques has been explored in conjunction with SE for the simultaneous assessment of myocardial ischaemia and atherosclerosis.10 Carotid plaque assessment has been shown to improve risk stratification of patients, especially those without myocardial ischaemia in whom the presence of carotid plaque was associated with a three-fold increased risk of death and myocardial infarction compared with those without carotid plaque.11 Focused carotid ultrasound for assessment of plaques has a short training period, can be performed within the allotted time period of an SE, and its use is also recommended by recent European guidelines.1 Using this diagnostic pathway, those with significant myocardial ischaemia could be triaged for invasive coronary angiography, while those with atherosclerosis alone could be managed with disease-modifying therapy. The authors did not compare the prognostic value of the ABCDE SE protocol in those with suspected CAD vs. known CAD, even though the number of patients in each group was similar. It is possible that the detection of myocardial ischaemia may have had more predictive value in those with recently symptomatic less advanced CAD than those with long established known CAD, compromised LV function, and more extensive, potentially vulnerable atherosclerotic plaques.12–14 The PROMISE trial which compared anatomical (CCTA) vs. functional testing strategies for the management of patients with suspected CAD showed no difference in outcomes and this was also replicated in the real-world setting with functional testing performed by conventional SE.12,13 In summary, the ABCDE SE protocol for the investigation of suspected CAD may be further refined by (i) optimizing the detection of ischaemia by incorporating UCAs for myocardial perfusion assessment during step A and (ii) adding a step for the assessment of atherosclerosis by carotid ultrasound to target the preventative treatment of non-obstructive atherosclerotic plaques (Graphial Abstract). Abnormal findings in steps C, D, or E in the absence of myocardial ischaemia, although of prognostic significance, are likely to have low specificities for the diagnosis of CAD. Furthermore, therapies targeted towards pathophysiological abnormalities in these steps have not been established and certainly there are no data to show that therapy improves prognosis. In contrast, the ABCDE protocol in known CAD and absence of myocardial ischaemia may be very useful for risk stratification, providing reassurance for low risk patients and for taking an informed decision regarding the need for invasive investigation in high risk patients. Conflict of interest: Roxy Senior: Speaker fees from Bracco, Milan, Italy and Lantheus Medical Imaging, Boston, USA, Philips Healthcare, Eindhoven, Holland; Rajdeep Khattar: Speaker fees from Bracco, Milan, Italy and Lantheus Medical Imaging, Boston, USA. The opinions expressed in this article are not necessarily those of the Editors of the European Heart Journal or of the European Society of Cardiology.
No takes yet. Share an insight, caveat, or question.
Senior et al. (2021) conducted an editorial in Coronary artery disease (n=3,574). Abnormal ABCDE stress echocardiography protocol vs. Normal stress echocardiography was evaluated on Mortality. An abnormal ABCDE stress echocardiography protocol across all five steps was associated with a mortality rate of 2.7%/year compared with 0.4%/year for a normal test.
Synapse has enriched 10 related papers. Consider them for comparative context: